Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
Australia
University of the Sunshine Coast (UniSC), Birtinya University of the Sunshine Coast (UniSC), Morayfield Pioneer Clinical Research, Sydney Germany
Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum Universitätsklinikum Erlangen - Medizinische Klinik 3, Erlangen Netherlands
Amsterdam University Medical Center, Amsterdam Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center), Leiden Spain
La Paz University Hospital, Madrid, Fuencarral-El Pardo Reina Sofia University Hospital, Córdoba, Poniente Sur University hospital Parc Tauli de Sabadell, Sabadell